Cart
sales@molnova.com
FASN-IN-2
CAS No. 1399177-37-7
FASN-IN-2( TVB-2640 )
Catalog No. M22842 CAS No. 1399177-37-7
FASN-IN-2 is a Fatty Acid Synthase (FASN) inhibitor(IC50 of 0.052 μM and an EC50 of 0.072 μM),with potential antineoplastic activity. TVB-2640 is an orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 217 | In Stock |
|
| 5MG | 187 | In Stock |
|
| 10MG | 315 | In Stock |
|
| 25MG | 530 | In Stock |
|
| 50MG | 733 | In Stock |
|
| 100MG | 1042 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2074 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFASN-IN-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionFASN-IN-2 is a Fatty Acid Synthase (FASN) inhibitor(IC50 of 0.052 μM and an EC50 of 0.072 μM),with potential antineoplastic activity. TVB-2640 is an orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity.
-
DescriptionFASN-IN-2 is a Fatty Acid Synthase (FASN) inhibitor(IC50 of 0.052 μM and an EC50 of 0.072 μM),with potential antineoplastic activity. TVB-2640 is an orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity. Upon administration, TVB-2640 binds to and blocks FASN, which prevents the synthesis of palmitate needed for tumor cell growth and survival. This leads to a reduction in cell signaling, an induction of tumor cell apoptosis and the inhibition of cell proliferation in susceptible tumor cells. FASN, an enzyme responsible for the de novo synthesis of palmitic acid, is overexpressed in tumor cells and plays a key role in tumor metabolism, lipid signaling, tumor cell survival and drug resistance; tumor cells are dependent on increased fatty acid production for their enhanced metabolic needs and rapid growth. Check for active clinical trials or closed clinical trials using this agent.
-
In VitroDenifanstat (compound 152) is a potent FASN inhibitor. Fatty Acid Synthase (FASN) inhibition prevents palmitoylation of SARS-CoV2 spike protein.
-
In Vivo——
-
SynonymsTVB-2640
-
PathwayMetabolic Enzyme/Protease
-
TargetFatty Acid Synthase
-
RecptorFASN
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1399177-37-7
-
Formula Weight439.55
-
Molecular FormulaC27H29N5O
-
Purity>98% (HPLC)
-
SolubilityDMSO:250 mg/mL (568.76 mM)
-
SMILESN#CC1=CC=C(C2CCN(C(C3=CC(C4=NC(C)=NN4)=C(C5CCC5)C=C3C)=O)CC2)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Johan D., et al. Heterocyclic modulators of lipid synthesis. WO2012122391A1.
molnova catalog
related products
-
L(-)-Carnitine
L-carnitine is constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
-
Gibberllin A7
Gibberillic acids (GA) are important plant growth hormones that promote plant cell growth and elongation. Gebberillins promote rapid stem and root growth, induce mitotic division and initiate (break dormancy) and increase seed germination rates.
-
Orlistat
Orlistat is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake.
